Pasar al contenido principal

DESARROLLO DE FARMACOS INHIBITORIOS FOTOCONMUTABLES Y METODOS DE ILUMINACION NO INVASIVA PARA NEUROMODULACION Y ESTUDIOS DE CIRCUITOS NEURONALES

PID2022-142609OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Photoswitchable COX-2-Selective Inhibitors as Light-Regulated Anti-Inflammatory Agents

  • Morales Jiménez, Amanda
  • Cruz, Alejandro
  • Pérez-Sánchez, Álex|||0000-0003-3636-3885
  • D'Avino, Danilo
  • Galassi, Gaia
  • Milano, Erica Ginevra
  • Bernareggi, Irene
  • Arenós-Bach, Carla|||0009-0002-0297-539X
  • Grazioso, Giovanni
  • Alibés, Ramon|||0000-0002-7997-2691
  • Hernando, Jordi|||0000-0002-1126-4138
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Rossi, Antonietta
  • Pistocchi, Anna
  • Matera, Carlo|||0000-0001-6939-3859
  • Busqué, Félix|||0000-0001-7566-4264
  • González Lafont, Àngels|||0000-0003-0729-2483
  • Lluch, José M.|||0000-0002-7536-1869
Despite their extensive use, the therapeutic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) remains significantly constrained by adverse side effects. This limitation primarily arises from insufficient selectivity, as current NSAIDs inhibit not only the inducible cyclooxygenase-2 (COX-2) isoform at sites of inflammation but also constitutive COX-2 in healthy tissues and, frequently, cyclooxygenase-1. To address this challenge, we developed photoswitchable NSAIDs that combine COX-2 selectivity with light-controlled activity to enable spatiotemporal confinement of the therapeutic effect at inflamed tissues. Following computational design and screening of a library of azoaromatic derivatives of celecoxib─the most widely used COX-2 selective NSAID─three photoswitchable analogues were synthesized, which exhibited reversible and efficient trans-cis photoconversion. Light-controlled and selective COX-2 inhibition was demonstrated for these compounds in vitro, reaching up to 5-fold potency enhancement in macrophage assays upon photoisomerization from the initial, dark-adapted trans isomer to the cis state. The best candidate displayed in vivo efficacy in a zebrafish model of acute inflammation, where administration of the photoinduced cis form reduced leukocyte recruitment at the wound site. These findings position photoswitchable NSAIDs as a promising alternative to conventional drugs for treating inflammation and related conditions, including cancer.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Brain state identification and neuromodulation to promote recovery of consciousness

  • Van Der Lande, Glenn J. M.
  • Casas-Torremocha, Diana
  • Manasanch, Arnau
  • Dalla Porta, Leonardo
  • Gosseries, Olivia
  • Alnagger, Naji
  • Barra, Alice
  • Mejias, Jorge F.
  • Panda, Rajanikant
  • Riefolo, Fabio
  • Thibaut, Aurore
  • Bonhomme, Vincent
  • Thirion, Bertrand
  • Clasca, Francisco
  • Gorostiza, Pau
  • Sanchez-Vives, Maria V.
  • Deco, Gustavo
  • Laureys, Steven
  • Zamora-López, Gorka
  • Annen, Jitka
Experimental and clinical studies of consciousness identify brain states (i.e. quasi-stable functional cerebral organization) in a non-systematic manner and largely independent of the research into brain state modulation. In this narrative review, we synthesize advances in the identification of brain states associated with consciousness in animal models and physiological (sleep), pharmacological (anaesthesia) and pathological (disorders of consciousness) states of altered consciousness in humans. We show that in reduced consciousness the frequencies in which the brain operates are slowed down and that the pattern of functional communication is sparser, less efficient, and less complex. The results also highlight damaged resting-state networks, in particular the default mode network, decreased connectivity in long-range connections and especially in the thalamocortical loops. Next, we show that therapeutic approaches to treat disorders of consciousness, through pharmacology (e.g. amantadine, zolpidem), and (non-) invasive brain stimulation (e.g. transcranial direct current stimulation, deep brain stimulation) have shown partial effectiveness in promoting consciousness recovery. Although some features of conscious brain states may improve in response to neuromodulation, targeting often remains non-specific and does not always lead to (behavioural) improvements. The fields of brain state identification and neuromodulation of brain states in relation to consciousness are showing fascinating developments that, when integrated, might propel the development of new and better-targeted techniques for disorders of consciousness. We here propose a therapeutic framework for the identification and modulation of brain states to facilitate the interaction between the two fields. We propose that brain states should be identified in a predictive setting, followed by theoretical and empirical testing (i.e. in animal models, under anaesthesia and in patients with a disorder of consciousness) of neuromodulation techniques to promote consciousness in line with such predictions. This framework further helps to identify where challenges and opportunities lay for the maturation of brain state research in the context of states of consciousness. It will become apparent that one angle of opportunity is provided through the addition of computational modelling. Finally, it aids in recognizing possibilities and obstacles for the clinical translation of these diagnostic techniques and neuromodulation treatment options across both the multimodal and multi-species approaches outlined throughout the review., NA is research fellow, OG and AT are Research Associates, and SL is the research director at Fonds de la Recherche Scientifique (FRS-FNRS). JA is a postdoctoral fellow at the Fonds voor Wetenschappelijk Onderzoek (FWO) (1265522N). The study was further supported by the University and University Hospital of Liège, the BIAL Foundation, the Belgian National Funds for Scientific Research (FRS-FNRS), the European Union's Horizon 2020 Framework Programme for Research and Innovation under Specific Grant Agreement No. 945539 (Human Brain Project SGA3), the FNRS PDR project (T.0134.21), the ERA-Net FLAG-ERA JTC2021 project ModelDXConsciousness (Human Brain Project Partnering Project), the fund Generet, the King Baudouin Foundation, the Télévie Foundation, the European Space Agency (ESA) and the Belgian Federal Science Policy Office (BELSPO) in the framework of the PROgramme de Développement d'Expériences scientifiques (PRODEX Programme), the Public Utility Foundation `Université Européenne du Travail', `Fondazione Europea di Ricerca Biomedica', the BIAL Foundation, the Mind Science Foundation, the European Commission, the Fondation Leon Fredericq, the Mind-Care foundation, the DOCMA project (EU-H2020-MSCA-RISE-778234), the National Natural Science Foundation of China (Joint Research Project 81471100) and the European Foundation of Biomedical Research (FERB Onlus). EU grants ICT-36-2020-101016787 (DEEPER), EIC Pathfinder GAP-101130883 (PHOTOTHERAPORT), and -EIC-2023-PATHFINDEROPEN-101130650 (META-BRAIN), Government of Catalonia AGAUR [Centres de Recerca de Catalunya (CERCA) Programme, 2021-SGR-01410; AGAUR 2021-SGR-01165 - NEUROVIRTUAL], Ministerio de Ciencia e Innovación (MICINN) grants PID2019-111493RB-I00 (DEEP RED) and PID2022- 142609OB-I00 (EPILLUM), PID2020-112947RB-I00 financed by Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI)/10.13039/501100011033 (CORTICOMOD), and Fundaluce and 'la Caixa' foundations (ID 100010434, agreement LCF/PR/HR19/52160010).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Photoswitchable Carbamazepine Analogs for Non-Invasive Neuroinhibition In Vivo

  • Camerin, L.
  • Maleeva, G.
  • Gomila, A.M.J
  • Suárez-Pereira, Irene
  • Matera, C.
  • Prischich, D.
  • Opar, E.
  • Riefolo, F.
  • Berrocoso Domínguez, Esther María
  • Gorostiza, P.
A problem of systemic pharmacotherapy is off-target activity, which causes adverse effects. Outstanding examples include neuroinhibitory medications like antiseizure drugs, which are used against epilepsy and neuropathic pain but cause systemic side effects. There is a need of drugs that inhibit nerve signals locally and on-demand without affecting other regions of the body. Photopharmacology aims to address this problem with light-activated drugs and localized illumination in the target organ. Here, we have developed photoswitchable derivatives of the widely prescribed antiseizure drug carbamazepine. For that purpose, we expanded our method of ortho azologization of tricyclic drugs to meta/para and to N-bridged diazocine. Our results validate the concept of ortho cryptoazologs (uniquely exemplified by Carbazopine-1) and bring to light Carbadiazocine (8), which can be photoswitched between 400–590 nm light (using violet LEDs and halogen lamps) and shows good drug-likeness and predicted safety. Both compounds display photoswitchable activity in vitro and in translucent zebrafish larvae. Carbadiazocine (8) also offers in vivo analgesic efficacy (mechanical and thermal stimuli) in a rat model of neuropathic pain and a simple and compelling treatment demonstration with non-invasive illumination.
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Photoswitchable COX-2-selective inhibitors as light-regulated anti-inflammatory agents

  • Morales Jimenez, Amanda
  • Cruz Sáez, Alejandro|||0000-0003-0928-0718
  • Pérez Sánchez, Álex
  • D'Avino, Danilo
  • Galassi, Gaia
  • Ginevra Milano, Erica
  • Bernareggi, Irene
  • Arenós Bach, Carla
  • Grazioso, Giovanni|||0000-0002-3261-9356
  • Alibes Arques, Ramon
  • Hernando Campos, Jordi
  • Gorostiza Langa, Pau
  • Rossi, Antonietta
  • Pistocchi, Anna
  • Matera, Carlo
  • Busqué Sanchez, Felix
  • González Lafont, Àngels
  • Lluch López, Josep Maria
Despite their extensive use, the therapeutic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) remains significantly constrained by adverse side effects. This limitation primarily arises from insufficient selectivity, as current NSAIDs inhibit not only the inducible cyclooxygenase-2 (COX-2) isoform at sites of inflammation but also constitutive COX-2 in healthy tissues and, frequently, cyclooxygenase-1. To address this challenge, we developed photoswitchable NSAIDs that combine COX-2 selectivity with light-controlled activity to enable spatiotemporal confinement of the therapeutic effect at inflamed tissues. Following computational design and screening of a library of azoaromatic derivatives of celecoxib-the most widely used COX-2 selective NSAID-three photoswitchable analogues were synthesized, which exhibited reversible and efficient trans-cis photoconversion. Light-controlled and selective COX-2 inhibition was demonstrated for these compounds in vitro, reaching up to 5-fold potency enhancement in macrophage assays upon photoisomerization from the initial, dark-adapted trans isomer to the cis state. The best candidate displayed in vivo efficacy in a zebrafish model of acute inflammation, where administration of the photoinduced cis form reduced leukocyte recruitment at the wound site. These findings position photoswitchable NSAIDs as a promising alternative to conventional drugs for treating inflammation and related conditions, including cancer., This work was supported by the “Ministerio de Ciencia, Innovación y Universidades” of Spain through projects PID2019-111493RB-I00, PID2022-142609OB-I00, PID2023-147140NB-I00, and PID2022-139826OB-I00. We also acknowledge CSUC (“Consorci de Serveis Universitaris de Catalunya”) for the allocation of computing resources, as well as from Generalitat de Catalunya through projects 2021 SGR 00064 and 2021 SGR 01410 and CERCA program. This study was supported by funds from the University of Milan, Piano di Sostegno alla Ricerca 2025, Linea 2. This research was supported for the in vitro studies by the Italian Ministry of University and Research (PRIN 2022 PNRR; MIUR CODE: P2022CNPH8, CUP: C53D23007850001). This research also received funding from the European Union Research and Innovation Program Horizon 2020 – Human Brain Project SG3 (945539), DEEPER (ICT-36-2020-101016787), and the European Innovation Council Pathfinder Open (PHOTOTHERAPORT, 101130883). J.H. is a Serra Húnter fellow., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Photoswitchable COX-2-selective inhibitors as light-regulated anti-inflammatory agents

  • Morales Jimenez, Amanda
  • Cruz Sáez, Alejandro
  • Pérez Sánchez, Álex
  • D'Avino, Danilo
  • Galassi, Gaia
  • Ginevra Milano, Erica
  • Bernareggi, Irene
  • Arenós Bach, Carla
  • Grazioso, Giovanni
  • Alibes Arques, Ramon
  • Hernando Campos, Jordi
  • Gorostiza Langa, Pau
  • Rossi, Antonietta
  • Pistocchi, Anna
  • Matera, Carlo
  • Busqué Sanchez, Felix
  • González Lafont, Àngels
  • Lluch López, Josep Maria
Despite their extensive use, the therapeutic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) remains significantly constrained by adverse side effects. This limitation primarily arises from insufficient selectivity, as current NSAIDs inhibit not only the inducible cyclooxygenase-2 (COX-2) isoform at sites of inflammation but also constitutive COX-2 in healthy tissues and, frequently, cyclooxygenase-1. To address this challenge, we developed photoswitchable NSAIDs that combine COX-2 selectivity with light-controlled activity to enable spatiotemporal confinement of the therapeutic effect at inflamed tissues. Following computational design and screening of a library of azoaromatic derivatives of celecoxib-the most widely used COX-2 selective NSAID-three photoswitchable analogues were synthesized, which exhibited reversible and efficient trans-cis photoconversion. Light-controlled and selective COX-2 inhibition was demonstrated for these compounds in vitro, reaching up to 5-fold potency enhancement in macrophage assays upon photoisomerization from the initial, dark-adapted trans isomer to the cis state. The best candidate displayed in vivo efficacy in a zebrafish model of acute inflammation, where administration of the photoinduced cis form reduced leukocyte recruitment at the wound site. These findings position photoswitchable NSAIDs as a promising alternative to conventional drugs for treating inflammation and related conditions, including cancer., This work was supported by the “Ministerio de Ciencia, Innovación y Universidades” of Spain through projects PID2019-111493RB-I00, PID2022-142609OB-I00, PID2023-147140NB-I00, and PID2022-139826OB-I00. We also acknowledge CSUC (“Consorci de Serveis Universitaris de Catalunya”) for the allocation of computing resources, as well as from Generalitat de Catalunya through projects 2021 SGR 00064 and 2021 SGR 01410 and CERCA program. This study was supported by funds from the University of Milan, Piano di Sostegno alla Ricerca 2025, Linea 2. This research was supported for the in vitro studies by the Italian Ministry of University and Research (PRIN 2022 PNRR; MIUR CODE: P2022CNPH8, CUP: C53D23007850001). This research also received funding from the European Union Research and Innovation Program Horizon 2020 – Human Brain Project SG3 (945539), DEEPER (ICT-36-2020-101016787), and the European Innovation Council Pathfinder Open (PHOTOTHERAPORT, 101130883). J.H. is a Serra Húnter fellow., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Brain state identification and neuromodulation to promote recovery of consciousness

  • Van Der Lande, Glenn J. M.
  • Casas-Torremocha, Diana
  • Manasanch, Arnau
  • Dalla Porta, Leonardo
  • Gosseries, Olivia
  • Alnagger, Naji
  • Barra, Alice
  • Mejias, Jorge F.
  • Panda, Rajanikant
  • Riefolo, Fabio
  • Thibaut, Aurore
  • Bonhomme, Vincent
  • Thirion, Bertrand
  • Clasca, Francisco
  • Gorostiza, Pau
  • Sanchez-Vives, Maria V.
  • Deco, Gustavo
  • Laureys, Steven
  • Zamora-López, Gorka
  • Annen, Jitka
Experimental and clinical studies of consciousness identify brain states (i.e. quasi-stable functional cerebral organization) in a non-systematic manner and largely independent of the research into brain state modulation. In this narrative review, we synthesize advances in the identification of brain states associated with consciousness in animal models and physiological (sleep), pharmacological (anaesthesia) and pathological (disorders of consciousness) states of altered consciousness in humans. We show that in reduced consciousness the frequencies in which the brain operates are slowed down and that the pattern of functional communication is sparser, less efficient, and less complex. The results also highlight damaged resting-state networks, in particular the default mode network, decreased connectivity in long-range connections and especially in the thalamocortical loops. Next, we show that therapeutic approaches to treat disorders of consciousness, through pharmacology (e.g. amantadine, zolpidem), and (non-) invasive brain stimulation (e.g. transcranial direct current stimulation, deep brain stimulation) have shown partial effectiveness in promoting consciousness recovery. Although some features of conscious brain states may improve in response to neuromodulation, targeting often remains non-specific and does not always lead to (behavioural) improvements. The fields of brain state identification and neuromodulation of brain states in relation to consciousness are showing fascinating developments that, when integrated, might propel the development of new and better-targeted techniques for disorders of consciousness. We here propose a therapeutic framework for the identification and modulation of brain states to facilitate the interaction between the two fields. We propose that brain states should be identified in a predictive setting, followed by theoretical and empirical testing (i.e. in animal models, under anaesthesia and in patients with a disorder of consciousness) of neuromodulation techniques to promote consciousness in line with such predictions. This framework further helps to identify where challenges and opportunities lay for the maturation of brain state research in the context of states of consciousness. It will become apparent that one angle of opportunity is provided through the addition of computational modelling. Finally, it aids in recognizing possibilities and obstacles for the clinical translation of these diagnostic techniques and neuromodulation treatment options across both the multimodal and multi-species approaches outlined throughout the review., NA is research fellow, OG and AT are Research Associates, and SL is the research director at Fonds de la Recherche Scientifique (FRS-FNRS). JA is a postdoctoral fellow at the Fonds voor Wetenschappelijk Onderzoek (FWO) (1265522N). The study was further supported by the University and University Hospital of Liège, the BIAL Foundation, the Belgian National Funds for Scientific Research (FRS-FNRS), the European Union's Horizon 2020 Framework Programme for Research and Innovation under Specific Grant Agreement No. 945539 (Human Brain Project SGA3), the FNRS PDR project (T.0134.21), the ERA-Net FLAG-ERA JTC2021 project ModelDXConsciousness (Human Brain Project Partnering Project), the fund Generet, the King Baudouin Foundation, the Télévie Foundation, the European Space Agency (ESA) and the Belgian Federal Science Policy Office (BELSPO) in the framework of the PROgramme de Développement d'Expériences scientifiques (PRODEX Programme), the Public Utility Foundation `Université Européenne du Travail', `Fondazione Europea di Ricerca Biomedica', the BIAL Foundation, the Mind Science Foundation, the European Commission, the Fondation Leon Fredericq, the Mind-Care foundation, the DOCMA project (EU-H2020-MSCA-RISE-778234), the National Natural Science Foundation of China (Joint Research Project 81471100) and the European Foundation of Biomedical Research (FERB Onlus). EU grants ICT-36-2020-101016787 (DEEPER), EIC Pathfinder GAP-101130883 (PHOTOTHERAPORT), and -EIC-2023-PATHFINDEROPEN-101130650 (META-BRAIN), Government of Catalonia AGAUR [Centres de Recerca de Catalunya (CERCA) Programme, 2021-SGR-01410; AGAUR 2021-SGR-01165 - NEUROVIRTUAL], Ministerio de Ciencia e Innovación (MICINN) grants PID2019-111493RB-I00 (DEEP RED) and PID2022- 142609OB-I00 (EPILLUM), PID2020-112947RB-I00 financed by Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI)/10.13039/501100011033 (CORTICOMOD), and Fundaluce and 'la Caixa' foundations (ID 100010434, agreement LCF/PR/HR19/52160010).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Three-photon infrared stimulation of endogenous neuroreceptors in vivo

  • Sortino, Rosalba|||0000-0002-8854-6782
  • Cunquero, Marina|||0000-0001-8093-8186
  • Castro-Olvera, Gustavo|||0000-0001-9843-3581
  • Gelabert, Ricard|||0000-0001-6506-5786
  • Moreno, Miquel|||0000-0002-2784-1307
  • Riefolo, Fabio|||0000-0002-6762-2619
  • Matera, Carlo|||0000-0001-6939-3859
  • Fernàndez-Castillo, Noèlia|||0000-0001-9948-0312
  • Agnetta, Luca
  • Decker, Michael
  • Lluch, José M.|||0000-0002-7536-1869
  • Hernando, Jordi|||0000-0002-1126-4138
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Gorostiza, Pau|||0000-0002-7268-5577
To interrogate neural circuits and crack their codes, in vivo brain activity imaging must be combined with spatiotemporally precise stimulation in three dimensions using genetic or pharmacological specificity. This challenge requires deep penetration and focusing as provided by infrared light and multiphoton excitation, and has promoted two-photon photopharmacology and optogenetics. However, three-photon brain stimulation in vivo remains to be demonstrated. We report the regulation of neuronal activity in zebrafish larvae by three-photon excitation of a photoswitchable muscarinic agonist at 50 pM, a billion-fold lower concentration than used for uncaging, and with mid-infrared light of 1560 nm, the longest reported photoswitch wavelength. Robust, physiologically relevant photoresponses allow modulating brain activity in wild-type animals with spatiotemporal and pharmacological precision. Computational calculations predict that azobenzene-based ligands have high three-photon absorption cross-section and can be used directly with pulsed infrared light. The expansion of three-photon pharmacology will deeply impact basic neurobiology and neuromodulation phototherapies.